Does Gabapentin Help Spinal Stenosis Pain?

Gabapentin is widely prescribed off-label for spinal stenosis pain, but the clinical evidence supporting its use is surprisingly thin. One early trial found meaningful improvements in walking distance and pain scores, yet a more recent meta-analysis pooling six studies found no significant pain reduction in the first two months of treatment. To complicate matters further, a 2021 clinical practice guideline explicitly recommends against gabapentin for the most common form of spinal stenosis symptoms. The gap between how often gabapentin is prescribed for this condition and how strong the evidence actually is deserves a closer look.

What the Trials Show

The most-cited trial in favor of gabapentin for spinal stenosis comes from a 2007 study that compared gabapentin plus standard treatment (a combination of physical therapy, lumbar corsets, and NSAIDs) against standard treatment alone. Patients who received gabapentin walked farther, reported less pain, and recovered more sensation in their legs than the control group, with all differences reaching statistical significance.¹ That sounds encouraging, and it’s the study many physicians point to when prescribing gabapentin for stenosis. But it was a small trial, and the patients knew which treatment they were receiving, which can inflate the perceived benefit.

A systematic review and meta-analysis published in 2023 tried to settle the question by pooling data from six studies involving about 390 patients. The results were underwhelming for the short term: at two weeks, four weeks, and eight weeks, there was no meaningful difference in pain scores between patients taking gabapentin or pregabalin and those taking a control treatment. Only at the three-month mark did a statistically significant difference emerge, and that finding was driven largely by pregabalin rather than gabapentin specifically.² Disability scores showed no significant improvement at any time point. And the side-effect profile was notably worse in the treatment groups, with adverse events roughly six times more likely than in the control groups.

A 2025 double-blind randomized controlled trial compared gabapentin, pregabalin, and placebo in 90 patients with neurogenic claudication from lumbar stenosis. All three groups improved significantly over four months. Gabapentin and pregabalin did not separate from placebo on pain scores, walking capacity, or symptom severity at any time point.³ In other words, patients got better regardless of whether they were taking the real drug or a sugar pill. That pattern is common in chronic pain research and makes it hard to attribute improvement to the medication itself.

Why Guidelines Recommend Against It

Given the evidence above, it’s less surprising that a 2021 clinical practice guideline for lumbar spinal stenosis causing neurogenic claudication recommended against gabapentin. The guideline panel evaluated the same body of literature and rated the evidence supporting gabapentin as very low quality. They also recommended against NSAIDs, opioids, muscle relaxants, pregabalin, and epidural steroid injections for this specific presentation.⁴

This doesn’t mean no one should ever try gabapentin for spinal stenosis. Guidelines reflect the best available evidence across populations, and individual patients sometimes respond well to treatments that don’t show strong group-level effects. But the recommendation does mean that gabapentin is not a first-line, evidence-backed choice for stenosis, and your doctor should be honest about that when prescribing it. If you’ve been told gabapentin is well-proven for stenosis, the reality is more nuanced than that framing suggests.

The Type of Pain Makes a Difference

Spinal stenosis can produce several distinct kinds of pain, and gabapentin doesn’t appear to work equally well against all of them. A study that assessed drug effectiveness based on the specific neurological symptoms patients reported found that patients with radicular pain (the shooting, burning kind that runs down a leg along a nerve root) responded meaningfully better to neuropathic pain medications than patients whose pain was related to spinal cord compression. The response rate for patients with spinal cord-related symptoms was significantly lower: only about 16% achieved a 50% reduction in pain scores, compared to much higher rates among patients with radicular pain.⁵

This matters because spinal stenosis often produces a mix of pain types. If your dominant symptom is aching, cramping heaviness in both legs when you walk (classic neurogenic claudication), gabapentin targets that poorly. If your main complaint is sharp, electric-shock pain radiating down one leg, you’re more likely to experience some benefit. Unfortunately, many prescribers don’t differentiate between these pain subtypes before handing over a gabapentin prescription. A careful clinical conversation about exactly what your pain feels like, where it is, and what triggers it can help predict whether gabapentin is even worth trying.

How Gabapentin Compares to Epidural Steroid Injections

One of the most common alternatives to gabapentin for nerve-related leg pain from spinal problems is an epidural steroid injection. A large multicenter randomized trial compared the two head-to-head in patients with lumbosacral radicular pain. At one month, both groups improved by roughly two points on a standard pain scale. At three months, similar improvements persisted. At neither time point was there a statistically significant difference between the injection group and the gabapentin group.⁶

That equivalence cuts both ways. On one hand, it means you might not need an invasive procedure if gabapentin offers a similar level of relief. On the other hand, the improvement in both groups was modest, and neither treatment produced dramatic pain resolution. For some patients, this trial’s message is that neither gabapentin nor epidural injections are likely to be a home run, and expectations should be calibrated accordingly. It also raises the question of whether the improvement in both groups was simply the natural course of the condition rather than a treatment effect, since many patients with stenosis symptoms improve somewhat over time regardless of intervention.

Gabapentin Versus Pregabalin

Pregabalin is gabapentin’s close chemical relative, and the two are often discussed interchangeably. But the evidence in spinal stenosis suggests they aren’t quite identical. The 2025 randomized trial found that pregabalin produced slightly greater improvement in quality-of-life scores compared to gabapentin at the one-month and two-month marks. That early advantage was small and disappeared by later follow-ups, and neither drug outperformed placebo on the other outcome measures.³ The meta-analysis similarly found that the three-month pain benefit was driven more by pregabalin than gabapentin.²

Pregabalin is absorbed more predictably than gabapentin, which has an unusual absorption ceiling: the more gabapentin you take, the smaller the fraction your gut actually absorbs. Pregabalin avoids that problem, which may explain why it sometimes edges ahead in trials. If your doctor has tried gabapentin and found it ineffective, switching to pregabalin might be worth discussing, though the overall evidence for either drug in stenosis remains weak. Side effects, including dizziness and sedation, were more common in both drug groups compared to placebo in that same trial.

Gabapentin Around Surgery

Where gabapentin has a clearer evidence base in the spinal stenosis world is not as a long-term treatment for chronic symptoms, but as a short-term tool around surgery. A meta-analysis of gabapentin given before or after lumbar laminectomy and discectomy found significantly lower pain scores at two hours, four hours, and 24 hours after the operation compared to patients who didn’t receive gabapentin.⁷ It also reduced postoperative anxiety. A separate review of perioperative gabapentinoid use in lumbar spine fixation surgery concluded that a single high dose of gabapentin given before surgery was safe and effective for controlling both early and late-stage postoperative pain.⁸

A trial specifically in patients undergoing lumbar canal stenosis surgery compared preoperative gabapentin, preoperative pregabalin, and placebo. Patients who received either drug before surgery had lower pain scores in the first four hours after the operation and needed less additional pain medication overall.⁹ If you’re scheduled for spinal stenosis surgery, gabapentin’s strongest role may be as a perioperative add-on to reduce your pain medication needs in the hours and days after the procedure rather than as a long-term chronic pain strategy.

Side Effects and the Opioid Interaction Risk

Gabapentin is often positioned as a safer alternative to opioids for chronic pain, and in many ways it is. But it’s not without risks, and one interaction deserves special attention. A large population-based study found that people prescribed both gabapentin and an opioid had roughly 49% higher odds of opioid-related death compared to those taking an opioid alone. At moderate and high gabapentin doses, the odds climbed to about 60% higher.¹⁰ Both drugs suppress breathing, and the combination can be dangerous, especially in older adults or people with sleep apnea.

This is directly relevant to spinal stenosis patients because many are already taking opioids when gabapentin is added to their regimen. If your doctor prescribes gabapentin alongside an opioid, it’s worth having a frank conversation about whether the combination is truly necessary and whether the gabapentin dose can be kept as low as possible.

Even without opioids, gabapentin commonly causes dizziness, drowsiness, and unsteadiness. In the 2025 randomized trial, these side effects were significantly more common in both the gabapentin and pregabalin groups than in the placebo group.³ For a population that tends to be older, already has balance issues from leg weakness or numbness, and is at elevated fall risk, those side effects aren’t trivial. A small study of a gastroretentive formulation of gabapentin (designed to release more slowly in the stomach) reported no significant adverse effects in 27 patients, with about a third experiencing marked therapeutic benefit, suggesting formulation and dosing approach may influence tolerability.¹¹

Practical Dosing Realities

One reason gabapentin sometimes fails in practice has nothing to do with the drug itself and everything to do with how it’s prescribed. Standard titration starts at 300 mg per day, increases by 300 mg daily over the first three days to reach 900 mg, then continues climbing to 1,200 mg and eventually up to 1,800 mg per day.¹² Many patients never reach an adequate dose because side effects during the ramp-up period (especially daytime drowsiness) cause them to stop early. Spreading doses more evenly throughout the day, or weighting more of the dose toward bedtime, can sometimes help patients tolerate the titration and actually reach a therapeutic level. If you tried gabapentin once at a low dose for a few weeks and gave up, you may not have given it a fair trial, though whether reaching a higher dose would have helped is genuinely uncertain given the mixed evidence.

Gabapentin also has that unusual absorption problem: the percentage your body absorbs drops as the dose per administration increases. At 300 mg, absorption is relatively efficient; at 600 mg or higher per dose, a meaningful fraction just passes through unabsorbed. This is why the drug is typically split into three daily doses rather than taken once. Extended-release formulations exist partly to work around this issue, delivering the drug more gradually and improving how much actually gets into your bloodstream.

When to Consider Gabapentin and When to Move On

The honest picture is that gabapentin sits in a gray zone for spinal stenosis. The strongest clinical guideline recommends against it. The best placebo-controlled trial shows it doesn’t separate from placebo. Yet some individual patients clearly do improve on it, and it remains one of the few oral options that even theoretically targets the nerve-related component of stenosis pain. For patients who cannot undergo surgery, who have failed physical therapy and activity modification, and who want to avoid opioids, a supervised trial of gabapentin is a reasonable thing to discuss with a physician, as long as both parties are clear-eyed about the probability that it won’t work.

If gabapentin doesn’t produce noticeable benefit after reaching a therapeutic dose for at least a month or two, continuing it doesn’t make sense. Many patients remain on gabapentin for months or years out of inertia, accumulating side-effect burden without clear benefit. A structured trial with a planned reassessment date, where you honestly evaluate whether your walking distance, leg pain, or daily function has meaningfully improved, is a better approach than an indefinite open-ended prescription. And if surgery is on the table, the evidence for gabapentin as a perioperative tool around that surgery is considerably more persuasive than its evidence as a standalone chronic treatment.

Other Neuropathic Pain Medications in Stenosis

Beyond gabapentin and pregabalin, a few other medications are sometimes tried for the nerve pain component of spinal stenosis, though none has a strong evidence base in this specific condition. Tricyclic antidepressants and duloxetine are commonly used for other neuropathic pain conditions like diabetic neuropathy, and some clinicians extrapolate from that evidence to stenosis. The 2021 guideline that recommended against gabapentin didn’t find strong support for these alternatives either. The fundamental challenge is that neurogenic claudication from stenosis is a mechanical problem: the spinal canal is too narrow, and the nerves are physically compressed. Medications can potentially quiet the nerve irritability and abnormal signaling that compression causes, but they can’t open up the canal or remove bone spurs. That mismatch between a structural problem and a pharmacological solution explains why drug treatments for stenosis generally show modest results at best, and why surgery, when symptoms are severe enough to warrant it, tends to produce more reliable relief.